illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Nanjing King-Friend Biochemical Pharmaceutical
Company logo

Nanjing King-Friend Biochemical Pharmaceutical | Sustainability Performance

https://www.nkf-pharma.com/?lang=en

Develops and manufactures biopharmaceutical products, producing generic injectables and active pharmaceutical ingredients for medical use.

2000

China

1,001 - 5,000 employees

Biotechnology

$500M - 1B in revenue

$25M - 100M in profitability

Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.

Sustainability Ranking & Industry Benchmark

#2590
Overallⓘ
#62
in Chinaⓘ
#42
in Biotechnologyⓘ

Sustainability Maturity

ⓘ
​​0123456789​​%

Sustainability Intent

ⓘ

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

57 out of 243

Overview
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies

Company logo
BioKangtai

China, Health Care, Biotechnology

Company logo
Basecare Medical

China, Health Care, Biotechnology

Company logo
Tianjin Teda Biomedical Engineering

China, Health Care, Biotechnology

Market cap ⓘTotal market value of the company's outstanding shares, calculated by multiplying the share price by the number of shares outstanding.
13.4B$, 2026▲38.7% YoY
Revenue ⓘTotal revenue reported in the company's financial statements for the specified reporting year, reflecting income generated from primary business activities. Expressed in millions of USD.
3.9B$, 2024▲0.2% YoY
R&D intensity ⓘResearch and development expenditure expressed as a percentage of revenue, reflecting the company's relative investment in innovation.
7.34%2024

Controversy level

Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

 Available
image report
Available

Sustainability employees

ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.

    Available in
    Scale package

    Access
  • Email
  • Email